What’s happening with BA.3.2/Cicada?

New COVID variant BA.3.2/Cicada expands—severity unclear

Recent reports say a new COVID-19 variant, BA.3.2, nicknamed “Cicada,” has been detected across the United States. Coverage indicates it has been found in multiple locations—specifically reported in 29 states and Puerto Rico—suggesting wider community spread than a single-cluster event.

Scientists and public-health experts are urging continued vigilance, but the news also emphasizes that there is no data showing increased severity tied to this variant. In other words, the immediate concern is surveillance and continued prevention behaviors, not confirmed evidence of worse outcomes.

Why this matters is that variant monitoring helps hospitals and clinicians anticipate shifts in circulating strains and can inform vaccine strategy, testing, and risk messaging. Even when transmissibility or severity isn’t clearly worse, the arrival of highly mutated lineages can influence how quickly cases spread and how long immunity holds.

Practical implications

• Expect guidance to focus on staying aware of symptoms and getting tested when appropriate.
• Continue using risk-reduction steps that remain effective against severe disease (such as vaccination where eligible, and masking in high-risk settings when advised).
• Treat claims about “worse disease” cautiously until severity data is available.

What remains unknown

The stories do not provide clinical severity results, hospitalization rates, or comparisons versus other circulating variants. They also do not specify whether any immunity escape is confirmed.

Bottom line: BA.3.2/Cicada is spreading geographically, but current coverage does not show it is inherently more severe.